Short Communication

The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer

DJ McKeown1, DJF Brown1, A Kelly2, AM Wallace2 and DC McMillan*1

1University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, UK; 2Department of Clinical Biochemistry, Royal Infirmary, Glasgow, UK

The relationship between circulating C-reactive protein concentrations and potential cytokine and receptor mediators (interleukin-6, leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), soluble IL-6 receptor, soluble gp130, soluble TNF receptor, interleukin-1 receptor antagonist and interleukin-8 (IL-8)) of this acute phase protein were examined in healthy subjects (n = 11) and patients with non-small-cell lung cancer (n = 50). Leukaemia inhibitory factor and CNTF were below detection limits in all controls and patients. C-reactive protein, interleukin-6, soluble gp130, soluble TNF receptor, interleukin-1 receptor antagonist and IL-8 concentrations were significantly elevated in cancer patients (P < 0.001). Cancer patients with elevated C-reactive protein concentrations had greater concentrations of interleukin-6 (P < 0.01) and interleukin-1 receptor antagonist (P < 0.05). On regression analysis only interleukin-6 was independently associated with C-reactive protein (r = 0.616, P < 0.001). Interleukin-6 is an important independent mediator of elevated C-reactive protein concentrations in patients with non-small-cell lung cancer.

Keywords: inflammatory cytokines; cytokine receptors; C-reactive protein; non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is the most common cause of cancer death in North America and Western Europe. Each year in the United Kingdom there are almost 39,000 new cases registered; only 7% are alive at 5 years (Cancerstats, 2004; www.cancerresearchuk.org). Most patients present with advanced inoperable disease, few are amenable to surgery and the results of radiotherapy and chemotherapy are poor.

It has recently become clear that the systemic inflammatory response, as evidenced by elevated circulating concentrations of C-reactive protein, is an important factor in the progressive nutritional decline of these patients and is a prognostic factor independent of stage, performance status and treatment (Scott et al, 2002; Forrest et al, 2003, 2004).

In the NSCLC patient the basis of the elevated C-reactive protein concentrations is unclear. Previous work has shown a strong positive association between interleukin-6 (IL-6) and C-reactive protein concentrations (Yanagawa et al, 1995; Scott et al, 1996). A number of other cytokines, which share structural homology and signal through the gp130-Jak-STAT pathway, have, however, been implicated in the elaboration of acute phase proteins in cancer (Heinrich et al, 1998). For example, in vitro studies have shown that leukaemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) stimulate increased acute phase protein production (Baumann et al, 1993). Additionally, there is evidence that soluble receptor subunits involved in IL-6 signal transduction, the soluble IL-6 receptor (sIL-6R) and the soluble gp130 receptor (sgp130), may also be important in regulating IL-6 activity and the acute phase protein response (Jones and Rose-John, 2002). Also, soluble TNF receptor (sTNF-RII), IL-1 receptor antagonist (IL-1Ra) and interleukin-8 (IL-8) have been reported to be associated with the systemic inflammatory response in lung cancer patients (Yanagawa et al, 1996; Simons et al, 1999; Alexandrakis et al, 2000).

The aim of the present study was to examine the relationship of the inflammatory cytokines, cytokine receptors and circulating concentrations of C-reactive protein in patients with NSCLC.

PATIENTS AND METHODS

Patients

Patients with a firm clinical or histological diagnosis of locally advanced or metastatic advanced NSCLC from palliative care centres in the West of Scotland were studied. Healthy subjects individuals were recruited from volunteers of the palliative care centres to serve as normal controls. The study was approved by the local research and ethics committee. All patients and controls were informed of the purpose of the study prior to entry and gave written, informed consent.

Experimental design

A blood sample was collected for routine laboratory analysis of white cell count, albumin and C-reactive protein. The minimum detectable concentrations for C-reactive protein were 6 mg l−1. The inter- and intra-assay variability of white cell count, albumin and C-reactive, protein were less than 10%.

A further blood sample was taken and centrifuged and the serum stored at −20 °C prior to analysis of inflammatory cytokines.
Clinical 1994

IL-1 Ra, 10 pg ml⁻¹/C0

sIL-6R, 8 ng ml⁻¹

White cell count (10⁹ l⁻¹)

<6 (<6 – <6)

IL-8 (pg ml⁻¹)

<10 (<10 – <10)

Median (range).

Table 1 Characteristics of healthy subjects and patients with NSCLC

| Characteristic                  | Healthy controls (n = 11) | NSCLC patients (n = 50) | P-value |
|--------------------------------|--------------------------|-------------------------|---------|
| Age                            | 66 (46–74)               | 64 (43–83)              | 0.894   |
| Sex (M/F)                      | 5/6                      | 24/26                   | 0.917   |
| BMI                            | 25.4 (22.4–28.9)         | 21.9 (14.8–64.2)        | 0.015   |
| Albumin (g l⁻¹)                | 43 (41–46)               | 40 (28–44)              | <0.001  |
| White cell count (10⁹ l⁻¹)     | 6.7 (4.1–8.4)            | 9.21 (5.1–23.5)         | <0.001  |
| C-reactive protein (mg l⁻¹)    | <6 (<6 – <6)             | 26 (6–207)              | <0.001  |
| IL-6 (pg ml⁻¹)                 | <2 (<2 – <2)             | 13 (<2–103)             | <0.001  |
| SfIL-6R (ng ml⁻¹)              | 16.1 (14.9–24.2)         | 18.8 (7.8–46.0)         | 0.291   |
| Sgp130 (ng ml⁻¹)               | 234 (175–290)            | 298 (227–448)           | <0.001  |
| sTNF-RII (ng ml⁻¹)             | 1.5 (1.2–7.5)            | 2.9 (1.5–6.8)           | 0.001   |
| IL-1 Ra (pg ml⁻¹)              | 286 (129–368)            | 539 (132–2129)          | <0.001  |
| IL-8 (pg ml⁻¹)                 | <10 (<10–<10)            | 13.9 (<10–118)          | <0.001  |

Median (range).

Table 2 Characteristics of inflammatory and noninflammatory patients with NSCLC

| C-reactive protein ≤ 10 mg l⁻¹ | Median <6 mg l⁻¹ | C-reactive protein > 10 mg l⁻¹ | Median 58 mg l⁻¹ | P-value |
|--------------------------------|------------------|-------------------------------|------------------|---------|
| Age                            | 61 (44–74)       | 66 (48–88)                    | 0.119            |
| Sex (M/F)                      | 5/9              | 19/17                         | 0.287            |
| BMI                            | 23.3 (19.7–31.0) | 21.9 (14.8–64.2)              | 0.287            |
| Albumin (g l⁻¹)                | 42 (38–47)       | 40 (28–46)                    | 0.014            |
| White cell count (10⁹ l⁻¹)     | 8.50 (5.60–18.87)| 9.55 (5.10–23.50)             | 0.305            |
| IL-6 (pg ml⁻¹)                 | 2.9 (2.0–22.2)   | 18.5 (2.0–103.0)              | 0.001            |
| SfIL-6R (ng ml⁻¹)              | 23.3 (14.0–30.7) | 18.8 (7.8–46.0)               | 0.216            |
| Sgp130 (ng ml⁻¹)               | 280 (218–330)    | 298 (227–448)                 | 0.572            |
| sTNF-RII (ng ml⁻¹)             | 2.5 (1.5–5.1)    | 3.2 (1.5–6.8)                 | 0.122            |
| IL-1 Ra (pg ml⁻¹)              | 378 (234–902)    | 724 (132–2128)                | 0.016            |
| IL-8 (pg ml⁻¹)                 | <10 (<10–90.6)   | 13.9 (<10–118.0)              | 0.152            |

Median (range).

and receptors. Circulating concentrations of the proinflammatory cytokines IL-6, LIF, CNTF and IL-8 and soluble receptors sIL-6R, sgp-130, IL-1Ra and sTNF-RII were measured using an enzyme linked immunosorbent assay (ELISA) technique. All samples were measured in duplicate and the mean value used. The minimum detectable concentrations were 2 pg ml⁻¹ for IL-6, 6.5 pg ml⁻¹ for sIL-6R, 8 ng ml⁻¹ for sgp130, 1 pg ml⁻¹ for sTNF RI, 14 pg ml⁻¹ for IL-1 Ra, 10 pg ml⁻¹ for IL-8, 8 pg ml⁻¹ for LIF and CNTF (Quantikine ELISA, R&D Systems Europe Ltd, Abingdon, UK). Inter- and intra-assay variability were less than 10% for all assays used.

Statistical analysis

Data are presented as median and range. Inflammatory cytokine and cytokine receptor concentrations below the threshold of sensitivity of the respective assays were expressed as equal to this threshold. Where appropriate, data were tested for statistical significance using the Mann–Whitney U test. As the distribution of C-reactive protein and the inflammatory cytokines and cytokine receptor concentrations were skewed, they were logarithmically transformed prior to stepwise multiple regression analysis for the examination of independent associations with C-reactive protein (SPSS version 11 Inc., Chicago, IL, USA).

RESULTS

The characteristics of the healthy controls and the NSCLC patients are shown in Table 1. Age and sex were similar in healthy subjects and patients. BMI and albumin were lower (P<0.05) and white cell count (P<0.001) and C-reactive protein (P<0.001) were higher in cancer patients compared with controls. Circulating concentrations of CNTF and LIF were less than the detection limit of the assay in all healthy subjects and cancer patients. Circulating concentrations of IL-6, sgp130, sTNF-RII, IL-1Ra and IL-8 were all significantly elevated in cancer patients compared with controls (P<0.01).

NSCLC patients were grouped according to whether or not they had evidence of a systemic inflammatory response (C-reactive protein >10 mg l⁻¹, Table 2). The groups were similar in terms of age, sex, BMI, white cell count and circulating concentrations of sIL-6R, sgp130, sTNF-RII, and IL-8. In the inflammatory group albumin concentrations were lower (P<0.05) and IL-6 (P<0.01) and IL-1Ra (P<0.05) concentrations were higher. In the cancer patients neither sIL-6R nor sgp130 concentrations were significantly associated with either IL-6 or C-reactive protein concentrations. In contrast, IL-6 concentrations were correlated with the white cell count (r = 0.294, P = 0.038).

In the cancer patients who had detectable C-reactive protein concentrations (n = 41), the relationship between log₁₀ C-reactive protein, log₁₀IL-6, and log₁₀IL-1Ra was examined in multiple linear regression analysis. Only IL-6 was independently associated with C-reactive protein (r = 0.616, P<0.001).

DISCUSSION

In the present study neither of the IL-6 type cytokines LIF and CNTF were detected in the sera of normal healthy controls or
patients with NSCLC. Although LIF and CNTF have been shown in rodent studies to induce an acute phase protein response and weight loss (Mori et al., 1991; Xu et al., 1998) our results are consistent with the largely undetectable levels reported in patients with rheumatoid arthritis (Okamoto et al., 1997). We cannot preclude, however, the possibility that these cytokines may be active systemically at concentrations below the sensitivity limit of current assays.

It has been proposed that soluble receptor subunits may be important in regulating IL-6 activity and C-reactive protein production (Jones and Rose-John, 2002). In the present study, however, neither sIL-6R nor sgp130 concentrations were significantly different between the inflammatory and noninflammatory cancer patients. Furthermore, neither sIL-6R nor sgp130 concentrations were significantly associated with either IL-6 or C-reactive protein concentrations in the cancer patients. Although measurement of soluble forms of interleukin-6 receptor and gp130 provides a total evaluation of the active concentrations of these mediators, both soluble receptor components exist in several forms and the ELISA determinations do not preclude specific changes in individual sgp130 or sIL-6R isoforms.

In the present study only IL-6 and IL-1Ra were significantly associated with C-reactive protein concentrations in patients with NSCLC. By multiple regression analysis, however, only IL-6 was independently associated with C-reactive protein concentrations. The results of the present cross-sectional study do not preclude the relationship between interleukin-6 and C-reactive protein simply reflecting the simultaneous release of these factors. Nevertheless, taken together these results would suggest independence and that C-reactive protein, a routinely available and well-standardised clinical laboratory measurement, is a useful surrogate measure of interleukin-6 activity in patients with NSCLC.

The source of IL-6 in patients with NSCLC remains uncertain since both a variety of host cells and the tumour cells have been shown to produce IL-6. In the present study, IL-6 was only weakly correlated with white cell count in the patients with NSCLC. This may suggest additional sources of IL-6 in these patients. For example, some lung cancer cell lines have been shown to produce IL-6. Indeed, there is some evidence that IL-6 produced by such tumour cells may act as an autocrine growth factor promoting the survival and invasion of the tumour into surrounding tissue (To et al., 2002).

To date, there have been few attempts to moderate the systemic inflammatory response in patients with cancer. Previous work has used a broad-brush approach with nonspecific anti-inflammatory agents (Lundholm et al., 1994; McMillan et al., 1999). The value of the present study is that it clearly identifies IL-6 from other candidate mediators of the increase in C-reactive protein concentration in a homogeneous cohort of cancer patients.

It also suggests that specific targeting of IL-6 signalling may be appropriate in patients with NSCLC. It is therefore of interest that anti-interleukin-6 receptor antibody has been shown to be clinically beneficial for the treatment of arthritis and Crohn’s disease and its action is associated with the suppression of C-reactive protein (Nishimoto et al., 2004; Ito et al., 2004).

In summary, interleukin-6 is an important independent mediator of elevated C-reactive protein concentrations in patients with NSCLC.

REFERENCES

Alexandrakis MG, Couloucheri SA, Bouros D, Mandalaki K, Karkavitsas N, Ellopoulos GD (2000) Evaluation of inflammatory cytokines in malignant and benign pleural effusions. Oncol Rep 7(6): 1327–1332

Baumann H, Ziegler SF, Mosley B, Morella KK, Pajovic S, Gearing DP (1993) Reconstitution of the response to leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in hepatoma cells. J Biol Chem 268: 8414–8417

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small cell lung cancer. Br J Cancer 90: 1704–1706

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89: 1028–1030

Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Greave L (1998) Interleukin-6-type cytokine signalling through the gp130/jak/STAT pathway. Biochem J 334: 297–314

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126: 889–996

Jones SA, Rose-John S (2002) The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochem Biophys Acta 1591: 251–263

Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svanberg G, Toftgard R, Vinnerberg H (1995) Treatment of rheumatoid arthritis with recombinant human interleukin-6 receptor: a double-blind, placebo-controlled trial. Arthritis Rheum 38: 972–979

Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O, Abe K (1991) Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51: 6656–6659

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761–1769

Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z (1997) The synthetic expression and serum levels of interleukin-6, interleukin-11, leukaemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 40: 1096–1105

Scott HR, McMillan DC, Grilly A, McArdle CS, Milroy R (1996) The relationship between weight loss and interleukin-6 in non-small-cell lung cancer. Br J Cancer 73: 1560–1562

Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87: 264–267

Simons JP, Schols AM, Buurman WA, Wouters EF (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (London) 97(2): 215–223

To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, Nakagome K, Nakamura T, Yamamoto K (2002) A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol 27(2): 220–226

Yanagawa H, Sone S, Kakashiyi H, Haku T, Yano S, Shinoara T, Ogura T (1995) Serum levels of interleukin-6 in patients with lung cancer. Br J Cancer 71(5): 1095–1098

Yanagawa H, Yano S, Haku T, Ohmoto Y, Sone S (1996) Interleukin-1 receptor antagonist in pleural effusion due to inflammatory and malignant lung disease. Eur Respir J 9(6): 1211–1216